The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules

V. K. Sharma, E. A. Ugheoke, R. Vasudeva, Colin Howden

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Because of its acid-labile nature, lansoprazole is usually administered as encapsulated enteric-coated granules. The gelatin capsule and acid-resistant coating of the granules have been considered essential for effective drug absorption and optimal bioavailability. Lansoprazole may attain effective plasma levels when given as non-encapsulated intact granules, but effects on intragastric acidity are unknown. Aim: To test the effectiveness of non-encapsulated, intact lansoprazole granules in suppressing intragastric acidity when administered through a gastrostomy. Methods: Eight men, each with an established gastrostomy underwent baseline 24 h intragastric pH monitoring while off any acid-suppressing medication. Via the gastrostomy, they then received 7 days of once-daily dosing with 30 mg lansoprazole as intact granules in 3 fl. oz, of orange juice. Intragastric pH monitoring was repeated on day 7. Results: Mean intragastric pH pre-dosing was 1.96 ± 0.5 (s.d.). This increased to 4.7 ± O.6 on day 7 (P < 0.0001). Median intragastric pH rose from 1.5 to 5.2 (P < 0.0001). Before lansoprazole, the proportions of time when intragastric pH was above 3, 4 and 5 were 23.2, 13.5 and 7.5%, respectively. Corresponding values after 7 days of lansoprazole were 81.1, 70.2 and 52.3% (P < 0.0001 for each comparison). Conclusion: Lansoprazole can effectively suppress intragastric acidity when given through a gastrostomy as intact, non-encapsulated granules in orange juice.

Original languageEnglish (US)
Pages (from-to)1171-1174
Number of pages4
JournalAlimentary Pharmacology and Therapeutics
Volume12
Issue number11
DOIs
StatePublished - Nov 18 1998

Fingerprint

Lansoprazole
Gastrostomy
Acids
Essential Drugs
Gelatin
Biological Availability
Capsules

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules. / Sharma, V. K.; Ugheoke, E. A.; Vasudeva, R.; Howden, Colin.

In: Alimentary Pharmacology and Therapeutics, Vol. 12, No. 11, 18.11.1998, p. 1171-1174.

Research output: Contribution to journalArticle

@article{3698a15656294b90bebac44b0b8b38c7,
title = "The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules",
abstract = "Background: Because of its acid-labile nature, lansoprazole is usually administered as encapsulated enteric-coated granules. The gelatin capsule and acid-resistant coating of the granules have been considered essential for effective drug absorption and optimal bioavailability. Lansoprazole may attain effective plasma levels when given as non-encapsulated intact granules, but effects on intragastric acidity are unknown. Aim: To test the effectiveness of non-encapsulated, intact lansoprazole granules in suppressing intragastric acidity when administered through a gastrostomy. Methods: Eight men, each with an established gastrostomy underwent baseline 24 h intragastric pH monitoring while off any acid-suppressing medication. Via the gastrostomy, they then received 7 days of once-daily dosing with 30 mg lansoprazole as intact granules in 3 fl. oz, of orange juice. Intragastric pH monitoring was repeated on day 7. Results: Mean intragastric pH pre-dosing was 1.96 ± 0.5 (s.d.). This increased to 4.7 ± O.6 on day 7 (P < 0.0001). Median intragastric pH rose from 1.5 to 5.2 (P < 0.0001). Before lansoprazole, the proportions of time when intragastric pH was above 3, 4 and 5 were 23.2, 13.5 and 7.5{\%}, respectively. Corresponding values after 7 days of lansoprazole were 81.1, 70.2 and 52.3{\%} (P < 0.0001 for each comparison). Conclusion: Lansoprazole can effectively suppress intragastric acidity when given through a gastrostomy as intact, non-encapsulated granules in orange juice.",
author = "Sharma, {V. K.} and Ugheoke, {E. A.} and R. Vasudeva and Colin Howden",
year = "1998",
month = "11",
day = "18",
doi = "10.1046/j.1365-2036.1998.00421.x",
language = "English (US)",
volume = "12",
pages = "1171--1174",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The pharmacodynamics of lansoprazole administered via gastrostomy as intact, non-encapsulated granules

AU - Sharma, V. K.

AU - Ugheoke, E. A.

AU - Vasudeva, R.

AU - Howden, Colin

PY - 1998/11/18

Y1 - 1998/11/18

N2 - Background: Because of its acid-labile nature, lansoprazole is usually administered as encapsulated enteric-coated granules. The gelatin capsule and acid-resistant coating of the granules have been considered essential for effective drug absorption and optimal bioavailability. Lansoprazole may attain effective plasma levels when given as non-encapsulated intact granules, but effects on intragastric acidity are unknown. Aim: To test the effectiveness of non-encapsulated, intact lansoprazole granules in suppressing intragastric acidity when administered through a gastrostomy. Methods: Eight men, each with an established gastrostomy underwent baseline 24 h intragastric pH monitoring while off any acid-suppressing medication. Via the gastrostomy, they then received 7 days of once-daily dosing with 30 mg lansoprazole as intact granules in 3 fl. oz, of orange juice. Intragastric pH monitoring was repeated on day 7. Results: Mean intragastric pH pre-dosing was 1.96 ± 0.5 (s.d.). This increased to 4.7 ± O.6 on day 7 (P < 0.0001). Median intragastric pH rose from 1.5 to 5.2 (P < 0.0001). Before lansoprazole, the proportions of time when intragastric pH was above 3, 4 and 5 were 23.2, 13.5 and 7.5%, respectively. Corresponding values after 7 days of lansoprazole were 81.1, 70.2 and 52.3% (P < 0.0001 for each comparison). Conclusion: Lansoprazole can effectively suppress intragastric acidity when given through a gastrostomy as intact, non-encapsulated granules in orange juice.

AB - Background: Because of its acid-labile nature, lansoprazole is usually administered as encapsulated enteric-coated granules. The gelatin capsule and acid-resistant coating of the granules have been considered essential for effective drug absorption and optimal bioavailability. Lansoprazole may attain effective plasma levels when given as non-encapsulated intact granules, but effects on intragastric acidity are unknown. Aim: To test the effectiveness of non-encapsulated, intact lansoprazole granules in suppressing intragastric acidity when administered through a gastrostomy. Methods: Eight men, each with an established gastrostomy underwent baseline 24 h intragastric pH monitoring while off any acid-suppressing medication. Via the gastrostomy, they then received 7 days of once-daily dosing with 30 mg lansoprazole as intact granules in 3 fl. oz, of orange juice. Intragastric pH monitoring was repeated on day 7. Results: Mean intragastric pH pre-dosing was 1.96 ± 0.5 (s.d.). This increased to 4.7 ± O.6 on day 7 (P < 0.0001). Median intragastric pH rose from 1.5 to 5.2 (P < 0.0001). Before lansoprazole, the proportions of time when intragastric pH was above 3, 4 and 5 were 23.2, 13.5 and 7.5%, respectively. Corresponding values after 7 days of lansoprazole were 81.1, 70.2 and 52.3% (P < 0.0001 for each comparison). Conclusion: Lansoprazole can effectively suppress intragastric acidity when given through a gastrostomy as intact, non-encapsulated granules in orange juice.

UR - http://www.scopus.com/inward/record.url?scp=0031766815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031766815&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.1998.00421.x

DO - 10.1046/j.1365-2036.1998.00421.x

M3 - Article

VL - 12

SP - 1171

EP - 1174

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11

ER -